chrisvoncsefalvay/vaers-outcomes huggingface dataset:
A patient who is deaf passed out almost immediately after receiving 1st dose of Moderna while sitting in the vaccination chair. The vaccinating nurse called for help and a nearby vaccinating nurse came to the patient's side. The patient was not breathing and the charge nurse was called over. The charge nurse asked other nurses to call 911. The vaccinating nurse was performing sternal rub on the patient and he was coming in and out of consciousness. The emergency cot was moved to the patient and the patient was laid on it with his legs up and he regained consciousness. Vitals were taken at 1:53 PM B/P 149/79 HR 57 Temp 98.2 Resp 0 O2 96% and again at 2:03 pm B/P 128/76 HR 69 Resp 16 O2 98%. EMS arrived at 2:05 PM and the patient refused transport to the hospital with his husband serving as interpreter for EMS. Patient left with husband. His gait was steady and no further interventions were needed.
Ischemic stroke 4/4/21 Continued fevers Brain fog Fatigue
Diagnosed by Dr at their office. Diagnosis - Hemi-retinal arterial occlusion of the left eye.  She has lost blood flow and vision in the bottom of her left eye. She first noticed this about 3 weeks to 1 month prior to the appointment on 23 Dec, 2022.
15 minutes after vaccination pt started itching.  arms legs back face.  Pt given 50 mg of Benedryl po.  15 minutes later lips and tongue tingling and chest tight.  pt used her inhaler and was given 125mg of solumedrol im  watched another 30 minutes and given script for Epi Pen.  Script filled.  Pt left office at 1035 am1232 called pt feeling groggy from benedryl but no itching tingling or chest tightness.
+ covid 8-7-22  Admitted with hematuria for weeks and had encephalopathy during hosp stat.  + for covid.   Had cysto which showed likely transitional cell cancer of bladder.  Treated for covid per protocol .  He improved but declined again and was felt not to have gotten over the covid.  he required levophed  and oxygen.  Ct showed  ifiltrates possible covid vs aspiration and placed on comfort measures and deceased on 9-7-22.
Information has been received from a medical assistant (also reported as "administrator"), concerning unknown number of patients of unknown age and gender. No pertinent medical history, drug reactions, allergies or concurrent conditions were reported. On unknown dates, the patients were vaccinated with unspecified improperly stored doses of VARIVAX (lot number M006722 with an expiration date of 08-FEB-2018, lot number M020899 with an expiration date of 27-APR-2018, lot number M023380 with an expiration date of 11-MAY-2018 and lot number reported as M027342 with an expiration date of 01-JUN-2018) (strength, dosage schedule, route and anatomical location were not reported). Concomitant medications were not provided. No adverse effects were reported. No product quality complaint was involved. This is one of several reports received from the same reporter. Additional information is not expected because the reporter did not consent for further follow up.
The patient received his vaccine on Thursday, 12/31/20 between 2:00pm and 2:30pm. The patient did not complain of any ADRs or fever immediately following the injection. However, the next day the patient fell in his room and when vitals were collected, he had a temperature of 102 F. Since the patient was febrile, him and his roommate were given rapid COVID tests, both of which were negative. The patient's PCR test has not come back yet. Per nursing report, the patient did not experience fever again over the weekend, it was a 1x occurrence. His temperature returned to normal on Saturday 1/2/21 and remained normal through Monday, 1/4/21. Besides fever, the patient did not complain of any other ADRs.
ADMINISTRATION ERROR: 10/02/21 - received PFIZER vaccination; on 11/01 received MODERNA vaccination. Body aches, nausea, vomiting, severe headache, cold sweats.
15min p/vax became very lightheaded & pale, became so sick couldn't sit in class;vomited twice before leaving school 930AM;vomited 3x during the afternoon a/5PM;did not exp a fever or diarrhea;
no adverse effects; Product reported as GARDASIL but lot # valid for GARDASIL 9; unspecified number of unspecified patients have been administered doses of improperly stored vaccines; This spontaneous report as received from a registered nurse, referring to a patient (gender and age not reported).  No information regarding the patient's medical history, concurrent conditions or concomitant therapies was provided.  On 27-MAR-2020 at 14:30 hours, the patient was vaccinated with an improperly stored dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) with a lot # reported as 1621931 (Reporter reported Gardasil with lot # 1621931 which was not valid for Gardasil . However, lot# 1621931 is valid for Gardasil 9) at a dose of 0.5 mL intramuscularly (IM) on the left arm (LA)for prophylaxis, however no adverse effects reported.   Administered dose of Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recomb. Vaccine (GARDASIL) experienced the temperature excursion above 9 degrees Celsius (15.5C) for 4 hour and 6 minutes. Digital data logger was involved. There were no previous temperature excursions reported.  This is one of the several reports received from the same reporter.   This case comes from a case previously considered non-valid, but per new information received (patient identifiers) the case was splitted and determined to be valid for a specific patient.; Sender's Comments:  US-009507513-2003USA002275:Original Case : 2003USA002275 US-009507513-2008USA008876: US-009507513-2008USA008911: US-009507513-2008USA008889: US-009507513-2008USA008885: US-009507513-2003USA002275: US-009507513-2008USA008879: US-009507513-2008USA008883: US-009507513-2008USA008881: US-009507513-2008USA008880: US-009507513-2008USA008875: US-009507513-2008USA008890: US-009507513-2008USA008877: US-009507513-2008USA008904: US-009507513-2008USA008921: US-009507513-2008USA008922: US-009507513-2008USA008923: US-009507513-2008USA008896: US-009507513-2008USA008925: US-009507513-2008USA008926: US-009507513-2008USA008927: US-009507513-2008USA008898: US-009507513-2008USA008928: US-009507513-2008USA008929: US-009507513-2008USA008899: US-009507513-2008USA008900: US-009507513-2008USA008930: US-009507513-2008USA008931: US-009507513-2008USA008901: US-009507513-2008USA008932: US-009507513-2008USA008903: US-009507513-2008USA008909: US-009507513-2008USA008907: US-009507513-2008USA008906: US-009507513-2008USA008920: US-009507513-2008USA008882:
felt hard to breath/feels like someone punching him; lung so sore inside; This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (felt hard to breath/feels like someone punching him) and PULMONARY PAIN (lung so sore inside) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012M20A) for COVID-19 vaccination.     Concurrent medical conditions included Lymphoma (non-Hodgkin's) and Blood pressure high. Concomitant products included RITUXIMAB (RITUXAN), ACICLOVIR SODIUM (ACYCLOVIR ABBOTT VIAL) and ATORVASTATIN for an unknown indication.    On 01-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Feb-2021, the patient experienced DYSPNOEA (felt hard to breath/feels like someone punching him) and PULMONARY PAIN (lung so sore inside). At the time of the report, DYSPNOEA (felt hard to breath/feels like someone punching him) and PULMONARY PAIN (lung so sore inside) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information provided.
Vomiting several times; Queasy in between; Initial information was received on 30-Sep-2020 regarding an unsolicited valid non-serious case from a pharmacist.  This case involves a 69 years old female patient who experienced vomiting several times (vomiting) and queasy in between (nausea), after she received INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  Medical history, past medical treatment(s), vaccination(s), concomitant medication and family history were not provided.   On 29-Sep-2020, the patient received a 0.7 mL dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT] Injection (lot number: UJ461AB and expiration date: 30-Jun-2021) via intramuscular route in the left arm for prophylactic vaccination.  On 29-Sep-2020 in night, the patient developed non-serious vomiting several times (vomiting) and queasy in between (nausea), on same day following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  Laboratory data was not reported.   No corrective treatment was received and patient was directed to call her doctor.  The patient was recovering from the events.
Initial information received on 20-Mar-2019 regarding an unsolicited valid non-serious case received from a nurse by phone. This case involves a 2 months old female patient who was vaccinated with 0.5 ml dose of PENTACEL (Batch number: reported as for ACTHIB C5594AA and for DTaP-IPV: C5444AA, expiry date: 27-Oct-2019) via intramuscular route in the right thigh on an unknown date. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included PNEUMOCOCCAL VACCINE CONJ 13V (CRM197); HEPATITIS B VACCINE and ROTAVIRUS VACCINE on an unknown date. It was a case of actual medication error due to inappropriate reconstitution technique. It was unknown if any adverse event occurred or not following the vaccination. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. Documents held by the sender: none.
I developed a fever a few hours after the vaccine and continued to have a fever the entirity of the next day. Additionally, I experienced some dizziness about 5 hours after receiving the vaccine
DAUGHTER CLAIMS THAT PATIENT DEVELOPED PNEUMONIA SECONDARY TO VACCINE.  VACCINATED 10/26/03, PNEUMONIA DIAGNOSED 12/11/03; PATIENT STILL NOT RECOVERED
Patient received his 4th dose of the pfizer 5-11 year covid vaccine on 5/31. On 6/3 he awoke with 3-4 episodes of emesis and fever with a tmax of 100.2 with chest pain that was worsening with inspiration. Based on EKG changes and and elevated BNP with normal troponins he was diagnosed with pericarditis and admitted to the hospital. He had an echocardiogram which was normal. He was treated with scheduled ibuprofen and released from the hospital on 6/4 with continued scheduled ibuprofen and short interval follow up.
local rxn swell lt thigh;small induration over lateral mid thigh 1.5cm;
A report has been received from a Health Professional concerning a 74 year old, male subject, who had been receiving FLUMIST QUADRIVALENT (Intranasal). FLUMIST QUADRIVALENT (intranasal) started on 28-Oct-2014. It was reported that the FLUMIST was administered to wrong patient population which started on 28-Oct-2014. The outcome of the event of administration to wrong patient population is unknown. The reporter's description of the event(s) was as follows: Not provided. The report was considered to be non-serious.
started having muscle stiffness; started having muscle spasms; This case was reported by a consumer via call center representative and described the occurrence of muscle stiffness in a female patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis.   On 30th December 2019, the patient received Boostrix. On 30th December 2019, immediately after receiving Boostrix, the patient experienced muscle stiffness and muscle spasm. On an unknown date, the outcome of the muscle stiffness and muscle spasm were not recovered/not resolved.   It was unknown if the reporter considered the muscle stiffness and muscle spasm to be related to Boostrix.  Additional details were provided as follows: Adverse event being filed with voicemail information only.  The age at the vaccination was not reported. The patient received Boostrix Vaccine for tetanus and shortly after started having muscle stiffness and muscle spasms and have been suffering ever since. The reporter consented to follow up. No additional details were provided at the time of the call.
On day 8 my arm started itching at the injection site.  By the next day it was red, swollen and indurated.  The area continued to expand even without scratching .  Consulted my physician by messaging.  He could not really advise me if I should proceed with the second dose but did report another colleague had 2 other patients reporting this same delayed reaction.
Redness and swelling in the right deltoid, joint pain throughout the body, and malaise since 10/2/23, followed by itching at the site starting 10/5/23.
No adverse effect noted. Resident administered expired Moderna vaccine, expired on 10/13/2021.
TIRED & WEAK. SHIVERING. DIARRHEA. PASSED OUT. FELL. BROKE WRIST. CUT CHIN. BLACK EYE. PUDDLE OF BLOOD ON FLOOR WRIST NOT HEALING: necrosis and sclerosis.  Flashes and floater in right eye.
Achy muscles, headache, nausea, stomach pains, fatigue, low grade fever of 99-100 degrees, chills, diarrhea, mild cough, painful injection site, and tight feeling in chest.
2nd not taken yet, beyond recommended interval; sweaty; I slept a lot; chest was hurting / Pain in the area where my heart at; sore; nausea; extremely tired; high grade fever 102.3; This spontaneous case was reported by a consumer and describes the occurrence of HYPERHIDROSIS (sweaty), SOMNOLENCE (I slept a lot), CHEST PAIN (chest was hurting / Pain in the area where my heart at), MYALGIA (sore) and NAUSEA (nausea) in a 26-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 004C21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19 (for month I was horribly sick) in October 2020. Concomitant products included AMFETAMINE ASPARTATE, AMFETAMINE SULFATE, DEXAMFETAMINE SACCHARATE, DEXAMFETAMINE SULFATE (ADDERALL) and MULTIVITAMINS [VITAMINS NOS] for an unknown indication, FISH OIL.    On 19-Aug-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 19-Aug-2021, the patient experienced HYPERHIDROSIS (sweaty), SOMNOLENCE (I slept a lot), CHEST PAIN (chest was hurting / Pain in the area where my heart at), MYALGIA (sore), NAUSEA (nausea), FATIGUE (extremely tired) and PYREXIA (high grade fever 102.3). On an unknown date, the patient experienced PRODUCT DOSE OMISSION ISSUE (2nd not taken yet, beyond recommended interval). The patient was treated with IBUPROFEN in August 2021 for Adverse event, at an unspecified dose and frequency. At the time of the report, HYPERHIDROSIS (sweaty), SOMNOLENCE (I slept a lot), CHEST PAIN (chest was hurting / Pain in the area where my heart at), MYALGIA (sore), NAUSEA (nausea), FATIGUE (extremely tired), PYREXIA (high grade fever 102.3) and PRODUCT DOSE OMISSION ISSUE (2nd not taken yet, beyond recommended interval) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 19-Aug-2021, Body temperature: high (High) high grade fever 102.3.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
Lower abdominal abscess; This spontaneous case was reported by a consumer and describes the occurrence of ABDOMINAL ABSCESS (Lower abdominal abscess) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No medical history reported).   On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced ABDOMINAL ABSCESS (Lower abdominal abscess) (seriousness criterion medically significant). At the time of the report, ABDOMINAL ABSCESS (Lower abdominal abscess) had not resolved. Not Provided          Treatment information was not provided.  Limited information regarding these events has been provided at this time and a causal relationship cannot be excluded.  The patient described the abscess as pre-existing, but as this was reported after 1st vaccine dose and prior to 2nd dose, it is not clear if it pre-exists the 1st dose; Sender's Comments: Limited information regarding these events has been provided at this time and a causal relationship cannot be excluded.  The patient described the abscess as pre-existing, but as this was reported after 1st vaccine dose and prior to 2nd dose, it is not clear if it pre-exists the 1st dose
AFTER 7 MINUTES IN OBSERVATIN PATIENT RPORTS FEELING UNWELL AND PALPITATIONS. TACHYCARDIA AND REGULAR RHYTTHM, DENIED CHEST PAIN, SOB AND DIZZINEZZ, INITIALLY SYMPOMS DECREASED UT RETURNED AFTER 20 MINUTES, PT C/O DIFFICULTY SWALLOWING. BANADRYL 50 MG IM.
SWELLING AND  ITCHY RASH IN LEFT ARM FROM DELTOID TO WRIST; Diarrhea; NODE UNDER LEFT ARMPIT SWELLING and VOMITING; Itchy rash; Vomiting; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (SWELLING AND  ITCHY RASH IN LEFT ARM FROM DELTOID TO WRIST), DIARRHOEA (Diarrhea), LYMPHADENOPATHY (NODE UNDER LEFT ARMPIT SWELLING and VOMITING), RASH PRURITIC (Itchy rash) and VOMITING (Vomiting) in an elderly female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product IBRUTINIB (IMBRUVICA) for Chronic lymphoid leukemia.    No Medical History information was reported.   On 10-May-2019, the patient started IBRUTINIB (IMBRUVICA) (Oral) 420 milligram. In September 2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (SWELLING AND  ITCHY RASH IN LEFT ARM FROM DELTOID TO WRIST), DIARRHEA (Diarrhea), LYMPHADENOPATHY (NODE UNDER LEFT ARMPIT SWELLING and VOMITING), RASH PRURITIC (Itchy rash) and VOMITING (Vomiting). At the time of the report, PERIPHERAL SWELLING (SWELLING AND  ITCHY RASH IN LEFT ARM FROM DELTOID TO WRIST) and RASH PRURITIC (Itchy rash) had not resolved and DIARRHEA (Diarrhea), LYMPHADENOPATHY (NODE UNDER LEFT ARMPIT SWELLING and VOMITING) and VOMITING (Vomiting) had resolved.            Concomitant product use was not provided by the reporter. On unknown dates, the patient experienced diarrhea, swelling and itchy rash in left arm from deltoid to wrist, node under left armpit swelling and vomiting. No treatment information was provided. This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   Reporter did not allow further contact
This spontaneous report as received from a health care professional refers to a patient of unknown age and gender who on 14-APR-2015 was vaccinated with improperly stored dose of ROTATEQ lot # K011663 (dose and route were not provided) which was under 12 hours excursion. No adverse effect observed or reported. This is one of several reports from the same reporter. Additional information has been requested.
Sore joints in upper body, neck, shoulders,  elbows , wrists & hands. Fingers are tingly and numbing , this is the most problematic symptom. Headaches come and go infrequently
VAERS completed because of being Tested positive for COVID-19 infection 14 or more days after being fully vaccinated. 1st dose 03/22/2021 pfizer,Lot# ER8727 2nd dose: 04/12/2021 Pfizer,Lot# EW0150 Diagnosed covid positive: 07/02/2021 Exposure: Symptoms:Fever, fatigue, headache.
Dark red area at injection site  Severe headache - has taken tylenol 10/05/2009 still has slight headache, redness has faded at injection site
Sore Arm; Diarrhea; This is a spontaneous report received from a non-contactable consumer, the patient. A 42-year-old non pregnant female patient received second dose of BNT162b2 (Pfizer BioNTech COVID-19 mRNA Vaccine Lot no: ER8727) on 26Mar2021 at 12:00 on right arm as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies. Concomitant medications Lipitor (MANUFACTURER UNKNOWN) for an unknown indication. The patient previously received first dose of BNT162b2 (Pfizer BioNTech COVID-19 mRNA Vaccine Lot no: EN6199) on 25Feb2021 at 14:00 on left arm as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination the patient was not diagnosed with COVID-19. Since vaccination, the patient had not been tested for COVID-19. On 27Mar2021, at 09:00 the patient experienced sore arm and diarrhea. Patient did not receive any treatment for events. The clinical outcome of the events sore arm and diarrhea was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Initial report received from a healthcare professional on 20 August 2012. An elderly female patient, whose age, medical history and concomitant medications were not reported, had received a dose of FLUZONE HD vaccine (batch number, route and anatomical site of administration were not reported) on an unspecified date. On an unspecified date, after vaccination the patient developed redness 4" below the vaccination site just above the elbow. Corrective treatment and laboratory investigations were not reported. As of 20 August 2012, the outcome was unknown. Documents held by sender: none.
Swollen lymph node in left arm pit; vaccine location=Left leg; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM3247) via an unspecified route of administration in the leg left on 15Feb2021 (at the age of 36-year-old), as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 17Feb2021, 48 hours after the vaccination, the patient experienced swollen lymph node in left arm pit. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen lymph node in left arm pit was recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
Red, itchy rash appearing first around injection site spreading to back and chest. Headache.
Systemic: Numbness (specify: facial area, extremities)-Mild, Additional Details: CHEST CRAMP, JOINT PAIN IN RIGHT ARM, PAIN ON RIGHT SIDE OF BODY, SYMPTOMS LAST 1 DAY